Production, Radiochemical Separation and Radiolabeling of Gold Nanoparticle Bioconjugates with 211At for Targeted Alpha Therapy

被引：0
|
作者：
Ghosh, S. [1 ,2 ]
Banerjee, D. [1 ,3 ]
Chakravarty, R. [1 ,2 ]
机构：
[1] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India
[2] Bhabha Atom Res Ctr, Radiopharmaceut Div, Mumbai, Maharashtra, India
[3] BARC, Variable Energy Cyclotron Ctr, Radiochem Div, Kolkata, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-280
引用
收藏
页码：S130 / S131
页数：2
相关论文
共 50 条
  • [41] Nanozeolite bioconjugates labeled with 223Ra for targeted alpha therapy
    Piotrowska, Agata
    Meczynska-Wielgosz, Sylwia
    Majkowska-Pilip, Agnieszka
    Kozminski, Przemyslaw
    Wojciuk, Grzegorz
    Cedrowska, Edyta
    Bruchertseifer, Frank
    Morgenstern, Alfred
    Kruszewski, Marcin
    Bilewicz, Aleksander
    NUCLEAR MEDICINE AND BIOLOGY, 2017, 47 : 10 - 18
  • [42] Manufacturing of [211At]NaAt for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer at Osaka University Hospital
    Ooe, Kazuhiro
    Naka, Sadahiro
    Shirakami, Yoshifumi
    Shimosegawa, Eku
    Kato, Hiroki
    Tatsumi, Mitsuaki
    Haba, Hiromitsu
    Toyoshima, Atsushi
    Watabe, Tadashi
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [43] Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)
    Watabe, Tadashi
    Hosono, Makoto
    Kinuya, Seigo
    Yamada, Takahiro
    Yanagida, Sachiko
    Namba, Masao
    Nakamura, Yoshihide
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (07) : 753 - 766
  • [44] Extended single-dose toxicity study of [211At]NaAt in mice for the FIH clinical trial of targeted alpha therapy for differentiated thyroid cancer
    Watabe, Tadashi
    Kaneda-Nakashima, Kazuko
    Ooe, Kazuhiro
    Liu, Yuwei
    Kurimoto, Kenta
    Toyoshima, Atsushi
    Shinohara, Atsushi
    Shirakami, Yoshifumi
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [45] Preclinical toxicity study of [211At]PSMA5 in mice and for the FIH clinical trial of targeted alpha therapy against refractory prostate cancer
    Watabe, T.
    Kaneda-Nakashima, K.
    Kadonaga, Y.
    Ooe, K.
    Sampunta, T.
    Yin, X.
    Haba, H.
    Kon, Y.
    Toyoshima, A.
    Cardinale, J.
    Giesel, F. L.
    Fukase, K.
    Tomiyama, N.
    Shirakami, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S345 - S345
  • [46] Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy
    Liu, Yang
    Zhou, Zhengyuan
    Feng, Yutian
    Zhao, Xiao-Guang
    Vaidyanathan, Ganesan
    Zalutsky, Michael R.
    Tuan Vo-Dinh
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 : 7297 - 7305
  • [47] Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
    Filosofov, Dmitry
    Kurakina, Elena
    Radchenko, Valery
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 94-95 : 1 - 19
  • [48] Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
    Huang, Xuhao
    Kaneda-Nakashima, Kazuko
    Kadonaga, Yuichiro
    Kabayama, Kazuya
    Shimoyama, Atsushi
    Ooe, Kazuhiro
    Kato, Hiroki
    Toyoshima, Atsushi
    Shinohara, Atsushi
    Haba, Hiromitsu
    Wang, Yang
    Fukase, Koichi
    PHARMACEUTICS, 2022, 14 (12)
  • [49] Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor
    Yonekura, Yoshiharu
    Toki, Hiroshi
    Watabe, Tadashi
    Kaneda-Nakashima, Kazuko
    Shirakami, Yoshifumi
    Ooe, Kazuhiro
    Toyoshima, Atsushi
    Nakajima, Hiroo
    Tomiyama, Noriyuki
    Bando, Masako
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [50] Production of Alpha Emitters for Targeted Alpha Therapy
    Morgenstern, A.
    Abbas, K.
    Bruchertseifer, F.
    Apostolidis, C.
    CURRENT RADIOPHARMACEUTICALS, 2008, 1 (03) : 135 - 143
12345